Pharmaceutical Technology lists ten of the most popular tweets in cardiovascular in November 2019, based on data from GlobalData’s Influencer Platform.
The top tweets were chosen from influencers as tracked by GlobalData’s Influencer Platform, which is based on a scientific process that works on pre-defined parameters. Influencers are selected after a deep analysis of the influencer’s relevance, network strength, engagement, and leading discussions on new and emerging trends.
Top tweets in cardiovascular in November 2019
1. Eric Topol’s tweet on wearable health devices
American cardiologist and digital medicine researcher, Eric Topol, shared an article detailing the growing significance of wearable health devices such as the Apple Watch series in maintaining heart health. Users can record the rhythm and heartbeat through the ECG app, which can help in detecting phenomenon such as atrial fibrillation or irregular heart rhythms.
A fingerprint touch on the ECG app for approximately 30 seconds helps in recording electrocardiograms or the electric pulses of the heart. The application is available on the Apple Watch 4 series and above, across regions and countries.
How to obtain a full 12-lead electrocardiogram via the @Apple watch (which normally gets one lead, lead 1)https://t.co/ro6MQxlhqs by @cobos_cardio @AnnalsofIM w/ demo tracings from patients with a heart attack and an instructive video pic.twitter.com/Ap5Slc0vMI
— Eric Topol (@EricTopol) November 25, 2019
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free sampleThank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Username: Eric Topol
Twitter handle: @EricTopol
Retweets: 263
Likes: 498
2. Gregg W Stone’s tweet on improved quality of life and reduced angina for patients with baseline angina
An interventional cardiologist, Gregg W Stone tweeted about the results from the ISCHEMIA trial, including improved quality of life and reduced angina in patients with any baseline angina with invasive surgery. According to the American Heart Association’s Scientific Sessions, stable coronary artery disease (CAD) and medium to severe Ischemia led to improvements in angina as well as the quality of life with an invasive strategy.
On the contrary, patients without angina did not experience an improved quality of life with invasive surgery, when compared to a conservative approach.
4/8 #ISCHEMIA: Substantial reduction in angina and improved QOL in pts w/any baseline angina with invasive approach. NNT to make 1 pt angina-free =~3-5! Benefits were sustained through 3+ yrs (unlike COURAGE in non-DES era). Minimal differences in asymptomatic pts.
— Gregg W. Stone MD (@GreggWStone) November 16, 2019
Username: Gregg W. Stone MD
Twitter handle: @GreggWStone
Retweets: 84
Likes: 165
3. Eric Topol’s tweet on cancer increasing the risk of deaths from cardiovascular disease
Eric Topol tweeted about cancer patients being at two to six times higher risk of dying from heart disease and stroke. The physician-scientist shared an article in his tweet detailing that nearly half the deaths, in breast, endometrial, prostate, and thyroid cancers are caused due to cardiovascular disease (CVD).
The study was carried out at the Penn State College of Medicine and Penn State Cancer Institute, Pennsylvania, US. Approximately 3.2 million cancer cases between 1973 and 2012 were compared with the general population. The results revealed that patients affected with bladder, womb, larynx, prostate, breast, and bowel cancers were at highest risk of dying from CVD.
Patients w/ #cancer have a 2-6 times higher mortality from cardiovascular disease than the general population https://t.co/LrfaYstH8F @escardio @ESC_Journals
report by @NicholasZaorsky, Kathleen Sturgeon @PSHResearch and collaborators; editorial by @mayocvonc pic.twitter.com/8TqiJyQnZl— Eric Topol (@EricTopol) November 25, 2019
Username: Eric Topol
Twitter handle: @EricTopol
Retweets: 99
Likes: 165
4. Dr Rohin Francis’ tweet on how incomplete data can be misleading
A Cambridge-trained cardiologist, Dr Rohin Francis tweeted about how earlier researches concluded, in the absence of right data, that smokers enjoyed better health following a heart attack when compared to non-smokers, although the former suffered more heart attacks.
Many studies suggest the paradoxical benefits of smokers being treated with thrombolytic therapy for a myocardial infarction (MI). Results revealed that smokers had their heart attacks at a younger age and hence have fewer comorbidities or heart disease than non-smokers.
A little tidbit for non-cardiologists who might not've heard of the Smoker's Paradox. WHY INCOMPLETE DATA CAN MISLEAD!
Yrs ago it was observed that although smokers had more heart attacks (MIs), they actually did *better* after having had one, compared to a non-smoker. wtf? pic.twitter.com/fctVWt7ga1
— Medlife Crisis (Rohin) (@MedCrisis) November 5, 2019
Username: Medlife Crisis (Rohin)
Twitter handle: @MedCrisis
Retweets: 94
Likes: 230
5. Mamas’ tweet on dapagliflozoc in reducing cardiovascular deaths
A consultant interventional cardiologist, Mamas tweeted about the benefits of dapagliflozoc in reducing cardiovascular deaths, hospitalisation, and urgent heart failure visits. The influencer shared an infographic from the American Heart Association (AHA) Scientific Sessions 2019, in the same tweet, to state that dapagliflozoc helped in reducing heart failures and cardiovascular deaths in standard therapy.
Additionally, patients with reduced ejection fraction (HFrEF) conditions showed improved symptoms, with or without Type 2 diabetes.
Dapa-HF benefit of dapaglifozocin consistent & of similar magnitude in DM and non-DM. 🔹decrease cv death, hospitalisation and urgent HF visit 🔹 in non-dm, same benefit even in norm hba1c. Should cardiologists be responsible for starting SGLT2i? #AHA2019 #aha19 @DrMarthaGulati pic.twitter.com/Q5Rlcb5mwi
— Mamas Mamas (@mmamas1973) November 16, 2019
Username: Mamas Mamas
Twitter handle: @mmamas
Retweets: 71
Likes: 145
6. David L Fischman’s tweet on Impella versus IABP in acute myocardial infarction
David L Fischman, a cardiologist, tweeted that Impella could have worse outcomes in a real-world scenario against the traditional intra-aortic balloon pump (IABP) used in treating acute myocardial infarction. This could further be complicated by a cardiogenic shock or the sudden inability of the heart to pump blood for the body, David added.
New studies and findings from the American Heart Association 2019 Scientific Sessions revealed that Impella could be associated with adverse events such as excessive bleeding, in-hospital deaths, and higher costs.
Let the discussion begin. In real world study Impella associated with worse outcomes compared to IABP in AMI-Cardiogenic Shock Patient undergoing #PCI #AHA19 pic.twitter.com/CLTc3t7nxy
— David L. Fischman (@fischman_david) November 17, 2019
Username: David L. Fischman
Twitter handle: @fischman_david
Retweets: 59
Likes: 147
7. Dr Deepak’s tweet on icosapent ethyl’s ability in reducing all-cause mortality in US patients
A professor of medicine at the Harvard Medical School, Dr Deepak L Bhatt shared an article highlighting that icosapent ethyl reduces cardiovascular risks, with a 30% reduction in all-cause mortality among US patients.
A total of3,146 patients were randomised under the Reduction of Cardiovascular Events with Icosapent Ethyl – Intervention Trial (REDUCE-IT), which was carried out to ascertain the benefit of icosapent ethyl among patients in the US, compared to those enrolled outside. The results revealed that the US group responded more effectively, reducing risks associated with cardiovascular deaths, strokes, and myocardial infarction.
Cardiovascular risk in the USA: Now we can REDUCE-IT w/ icosapent ethyl, including a statistically significant 30% reduction in all-cause mortality in US patients! REDUCE-IT USA: Results from the 3,146 Patients Randomized in the United States | Circulation https://t.co/YxGVlCmYUq
— Dr. Deepak L. Bhatt (@DLBHATTMD) November 11, 2019
Username: Dr. Deepak L. Bhatt
Twitter handle: @DLBHATTMD
Retweets: 58
Likes: 160
8. Mamas’ tweet on the best practices to prevent radial occlusion (RAO)
A professor and consultant interventional cardiologist, Mamas shared an article on how to prevent radial occlusion (RAO) after a transradial diagnostic angiography and intervention. One of the biggest complications associated with RAO is that the same radial artery cannot be used for future procedures.
Transradialaccess (TRA) is a common procedure currently and is often associated with less bleeding and vascular problems.The incidence of RAO remains high, therefore. The article stresses on the adoption of simple techniques to reduce RAO.
1. Our consensus paper re best practices to decrease radial occlusion (RAO) led by Ivo Bernat, adel aminian & Olivier bertrand published with @SVRaoMD @Radial_ICG @samirpancholy @nolanjimradial https://t.co/4A3rMxb6ih RAO most frequent complication of #RadialFirst @rwyeh pic.twitter.com/IEr8cL320T
— Mamas Mamas (@mmamas1973) November 19, 2019
Username: Mamas Mamas
Twitter handle: @mmamas1973
Retweets: 52
Likes: 120
9. SekKathiresan’s tweet on the effectiveness of low-dose Colchicine in reducing cardiovascular events
A physician-geneticist, SekKathiresan shared an article on the safety and efficacy of low-dose Colchicine for reducing cardiovascular events. The article by the New England Journal of Medicine further stated that a randomised trial was conducted on patients diagnosed with myocardial infarction. The patients were administered with low-dose (0.5mg) Colchicine or placebo daily to detect cardiovascular risks, deaths, strokes, hospitalisation for angina, diarrhoea, and pneumonia.
The results revealed that the Colchicine group reported lower risks associated with ischemic cardiovascular events, compared to the placebo group.
This is wild!
Addition of low-dose colchicine (0.5mg) (an anti-inflammatory drug around for centuries)
to standard-of-care
significantly reduces CV events
Further evidence to support this concept: reduce inflammation to Rx CADhttps://t.co/kVgEJeMWQm pic.twitter.com/7aP35uOmrp
— Sek Kathiresan MD (@skathire) November 16, 2019
Username: SekKathiresan MD
Twitter handle: @skathire
Retweets: 42
Likes: 113
10. Dr Purvi’s tweet on long-term cardiovascular risks in women
A cardiologist based in California, Dr Purvi Parwani tweeted on the cardiovascular risks associated with hypertension in pregnancy. She shared an article posted by the Journal of the American College of Cardiology (JACC), which stated that a history of hypertensive disorder of pregnancy (HDP) should be helpful in detecting cardiovascular risks in women.
A study carried out on 220,024 women revealed that HDP contributes aggressively to the development of cardiovascular diseases. It also found that cardiovascular risks were enhanced after HDP due to chronic hypertension.
Important paper for #womenCVD in @JACCJournals on HypertensiveDiseaseofPregnancy(HDP)
-👩🦰40-69 years with ≥1birth n= 220,024
– HDP -> ⬆️CAD, CHF, AS, MR
– The development of chronic HTN doesn't explain all the associated riskhttps://t.co/wwUe9ckJoQ pic.twitter.com/DejoNcUi3Y— Dr. Purvi Parwani (@purviparwani) November 21, 2019
Username: Dr.PurviParwani
Twitter handle: @purviparwani
Retweets: 38
Likes: 79